Skip to main content

Philips brings clarity to every moment of cancer care with new patient-centered innovations at ASTRO 2021

Philips Multimodality RT Simulation Workspace

Philips Multimodality RT Simulation Workspace dialog

October 21, 2021

  • Multimodality RT Simulation Workspace provides a single space for multimodality image fusion and contouring
  • New imaging platforms MR – Ingenia RT XD – and Spectral CT 7500 support precise treatment planning
  • Deepened cross-portfolio collaboration with Elekta utilizes complementary capabilities to further enhance patient care

Amsterdam, the Netherlands and Chicago, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced new innovations that will help improve cancer care across the patient journey at the American Society for Radiation Oncology (ASTRO) annual meeting (Chicago, USA, 24-27 October). During the event, Philips will debut its Multimodality RT Simulation Workspace, a new precision medicine application that provides a vendor-agnostic single space for simulation, multimodality image fusion and contouring. New MR and CT imaging systems tailored for the needs of radiation therapy will also be showcased, delivering breakthroughs in imaging and treatment planning. Philips will also highlight its deepened strategic partnership with Elekta to support the ambition of providing clear care pathways and predictable outcomes for every cancer patient.

Today, cancer care is a long, complex journey through various stages, settings, and providers, putting a significant burden on both patients and clinicians. The number of new cancer cases is expected to rise by about 70% over the next two decades [1]. At the same time, oncology care is transforming, driven by an increasingly precise diagnosis of each tumor, and a continuously expanding range of therapy options. To fully capitalize on these challenges and opportunities, healthcare providers require integrated solutions throughout the entire cancer care pathway, from diagnosis to treatment and follow-up.

“Enhanced through strategic partnerships, our end-to-end oncology solutions span the patient pathway and the multidisciplinary specialties, integrating data and enabling collaboration, all with the aim of improving patient and staff satisfaction and outcomes,” said Ardie Ermers, General Manager Oncology Solutions at Philips. “At this year’s ASTRO meeting we’re highlighting how we’re connecting clinical and operational teams with the information they need to optimize and personalize cancer care.”

Bringing clarity in therapy planning closer to the point of care with Multimodality RT Simulation Workspace
With images and data often siloed in different systems, the complexity of image fusion and contouring can lengthen patient time to treatment. Integrating seamlessly into the simulation workflow, Multimodality RT Simulation Workspace, a new precision medicine application, is designed to help physicians define tumor volume and surrounding organs-at-risk through a versatile multimodality image platform which connects to both Philips and non-Philips imaging devices or a Picture Archiving and Communication System (PACS) to access image datasets such as CT, MR, PET, Spectral CT and Cone Beam CT. These capabilities provide better access to a task-centered, vendor neutral solution that efficiently utilizes all available images and data in one central location.

Innovations in MR and CT simulation deliver advances in imaging and treatment planning
With the company’s strong track record of bringing continuous innovations to expand the role of MRI in radiation therapy, the next-generation Philips MR – Ingenia RT XD ­– MR simulation platform has been designed around the needs of radiation oncology, combining ease-of-use, streamlined integration and versatility. The platform can be easily adapted for different procedures, including external beam radiation therapy (EBRT), proton therapy and brachytherapy planning. The new Couch Top RT XD with Unity indexing further extends the compatibility between the Philips MR – Ingenia RT XD – and Elekta Unity, supporting greater consistency in both image quality and imaging and positioning workflows that enhance reproducibility, help accelerate learning curves and drive continuity across the care path.

The recently-introduced Spectral CT 7500 system delivers high quality spectral images for every patient on every scan 100% of the time to help improve disease characterization, and reduce rescans and follow-ups, all at the same dose levels as conventional scans. Unlocking the clinical value of dual-energy CT for radiation oncology applications, Spectral CT allows for optimization of lesions that may represent cancer. By capturing additional information such as electron density and effective atomic number, Spectral CT enables physicians to quantify physiological processes such as perfusion and ventilation, enhancing treatment planning.

Philips is collaborating with MIM Software to integrate its Contour ProtégéAI next-generation deep learning segmentation on its CT – Big Bore RT – platform, providing automatically segmented ‘Organ at Risk’ segmentation immediately after the simulation exam [2].

Further expansion of precision medicine application portfolio
Also being introduced at ASTRO, Multidisciplinary Team Orchestrator virtually connects and securely integrates multi-disciplinary teams and data across the patient cancer journey. Together with Multimodality RT Simulation Workspace, applications already available from Philips that advance precision oncology through integrated care, pathway orchestration, and clinical decision support, include:

  • Lung Cancer Orchestrator, a proactive patient management system for lung cancer screening and incidental findings and the orchestration of lung cancer care
  • Oncology Pathways that are created by oncologists for oncologists, covering both medical and the newly-introduced radiation oncology pathways. Customers become collaborators, providing input into the ever-evolving pathways
  • Genomics Workspace, bringing genomic data alongside disease histology and patient phenotype for a comprehensive biomarker-informed diagnostic and therapeutic picture

Partnering to benefit patients throughout the care pathway
In June, Philips and Elekta announced that the two healthcare leaders would deepen their strategic partnership in precise and individualized oncology care. The strengthened strategic partnership intends to further deliver an excellent experience in diagnosis and adaptive, personalized treatments for clinicians, shorter treatment times and precise therapy for patients, and lowered costs of care for healthcare providers. As part of the partnership, Philips will develop seamless integration between its precision medicine applications and Elekta’s MOSAIQ Plaza integrated radiotherapy software suite, enhancing end-to-end decision making and treatment implementation.

For more information about Philips’ presence at ASTRO 2021 follow @PhilipsLiveFrom for updates throughout the event.

[1] WHO International Agency for Research on Cancer https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf
[2] Big Bore RT with Contour ProtégéAI is only available in the USA
Multimodality RT Simulation Workspace is a new feature of the TumorLoc module, part of Pinnacle RTPS. Both TumorLoc and Pinnacle are FDA cleared

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978 221 8919
E-mail: kathy.oreilly@philips.com

Mark Groves
Philips Global Press Office
Tel.: +31 631 639 916
Email: mark.groves@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.